British officials announced on May 7 that an alternative vaccine against COVID will be provided to people under the age of 40, a type developed by the pharmaceutical company AstraZeneca and the University of Oxford.. This is because the risk of blood clots is small, although this must also be done under conditions where the number of cases is small and other vaccines are available.
What did the British officials report?
On Friday, May 7, the British government reported that for the few reported cases of blood clots, they should provide AstraZeneca’s alternative vaccine to people under 40. Even other countries suggest that it is best to give this drug only to the elderly..
On the other hand, the Joint Committee on Vaccination and Immunization (JCVI) stated: The recommendation reflects the low level of COVID infection in the UK and the availability of other vaccines produced by Pfizer and Moderna.
In addition, officials mentioned that they will still provide the first dose of this vaccine to all adults by the end of July. In this regard, they emphasized that if there are no other drugs available, it is best for these people to receive AstraZeneca injections..
In this regard, Wei Shen Lim, COVID President of JCVI, mentioned the following: “As the incidence of COVID-19 continues to be under control, We recommend that adults between the ages of 18 and 39 who have no basic health conditions provide alternatives to Oxford/AstraZeneca vaccine, If any, and will not cause delays in vaccine application,.
It should be noted that the initial suggestion was only Another vaccine will be applied to people under 30.
What is a blood clot case report in the UK?
According to the British drug regulatory agency MHRA, The incidence of blood clots per million doses of AstraZeneca vaccine was found to be 17.4 in people between 30 and 39 years old, And there are 10.5 blood clots per million doses.
In addition, it is reported that people between the ages of 30 and 39 have 4.5 deaths per million doses.By comparison, the total number of reported clot deaths per million doses was 2.1.
In this regard, MHRA CEO June Raine said the benefits of AstraZeneca vaccine “They continue to exceed the risk of most people”.
*Information from AstraZeneca